4//SEC Filing
Atkisson Erik 4
Accession 0001999371-24-000960
CIK 0001724979other
Filed
Jan 25, 7:00 PM ET
Accepted
Jan 26, 4:38 PM ET
Size
10.6 KB
Accession
0001999371-24-000960
Insider Transaction Report
Form 4
Atkisson Erik
General Counsel and CCO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−60,251→ 0 totalExercise: $1.21→ Common Stock (60,251 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−82,882→ 0 totalExercise: $9.34→ Common Stock (82,882 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−37,118→ 0 totalExercise: $9.34→ Common Stock (37,118 underlying)
Footnotes (1)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Documents
Issuer
Rain Oncology Inc.
CIK 0001724979
Entity typeother
Related Parties
1- filerCIK 0001885915
Filing Metadata
- Form type
- 4
- Filed
- Jan 25, 7:00 PM ET
- Accepted
- Jan 26, 4:38 PM ET
- Size
- 10.6 KB